02196 復星醫藥
按盘价 
19.810 +1.020 (+5.428%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | 2.839% | 2.400% | 2.175% | 3.730% | 5.347% |
| 股东资金回报率 (%) | 7.027% | 5.965% | 5.320% | 8.933% | 12.431% |
| 资本运用回报率 (%) | 4.032% | 3.464% | 3.011% | 5.063% | 7.397% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 49.877% | 47.774% | 47.646% | 47.115% | 47.947% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 19.280% | 16.686% | 12.742% | 13.519% | 17.473% |
| 税前边际利润率 (%) | 12.319% | 10.191% | 7.944% | 10.455% | 15.548% |
| 纯利率 (%) | 8.122% | 6.771% | 5.815% | 8.530% | 12.167% |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 0.929 X | 0.921 X | 1.001 X | 1.059 X | 1.038 X |
| 速动比率 (X) | 0.757 X | 0.727 X | 0.778 X | 0.853 X | 0.851 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 48.505% | 48.991% | 50.121% | 49.532% | 48.179% |
| 总债项 / 总资产比率 (%) | 30.291% | 30.646% | 30.845% | 28.064% | 27.157% |
| 净债项 / 总资产比率 (%) | 19.372% | 19.129% | 18.773% | 12.901% | 16.093% |
| 总债项 / 股东资金比率 (%) | 74.643% | 76.203% | 76.650% | 67.502% | 64.702% |
| 长期债项 / 股东资金比率 (%) | 30.620% | 27.498% | 34.076% | 28.844% | 24.777% |
| 净债项 / 股东资金比率 (%) | 47.737% | 47.565% | 46.650% | 31.031% | 38.341% |
| 净现金 / (债项) ($) | (232.49亿) | (224.61亿) | (212.94亿) | (138.18亿) | (150.06亿) |
| 每股净现金 / (债项) ($) | (8.808) | (8.450) | (7.968) | (5.171) | (5.855) |
| 总债项 / 资本运用比率 (%) | 43.490% | 44.999% | 43.914% | 40.723% | 39.611% |
| 利息盈利率 (X) | 5.040 X | 3.912 X | 3.473 X | 5.753 X | 8.346 X |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 118.547日 | 126.388日 | 121.864日 | 97.316日 | 95.945日 |
| 应收贸易帐周转率日数 (日) | 76.747日 | 70.005日 | 67.610日 | 56.897日 | 50.964日 |
| 应付贸易帐周转率日数 (日) | 48.997日 | 54.233日 | 55.056日 | 47.270日 | 39.223日 |
| 备注： | 实时报价更新时间为27/03/2026 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB 3,370,562 |
| 增长率 | 21.686% |
| 每股盈利/(亏损) | RMB 1.270 |
| 每股账面资产净值 (¥) | RMB 18.451 |